Sirijatuphat, 93 patient favipiravir early treatment RCT: 64% faster improvement [p=0.0005], 43% lower progression [p=0.25], and 4% worse viral clearance [p=0.87] https://c19p.org/sirijatuphat2
copied to clipboard
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
et al., medRxiv, doi:10.1101/2022.06.06.22275902
RCT 93 patients in Thailand showing significantly faster clinical improvement with favipiravir treatment. 1800mg favipiravir bid day 1, 800mg bid 5-14 days until PCR-.
|
time to clinical improvement, 63.9% lower, HR 0.36, p < 0.001, treatment 62, control 31, primary outcome.
|
|
clinical improvement, 89.9% lower, OR 0.10, p < 0.001, treatment 62, control 31, logistic regression, day 14, RR approximated with OR.
|
|
risk of mild pneumonia, 42.9% lower, RR 0.57, p = 0.25, treatment 8 of 62 (12.9%), control 7 of 31 (22.6%), NNT 10.
|
|
risk of no viral clearance, 4.2% higher, HR 1.04, p = 0.87, treatment 62, control 31, adjusted per study.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Sirijatuphat et al., 6/8/2022, Randomized Controlled Trial, Thailand, South Asia, peer-reviewed, 9 authors, trial TCTR20200514001.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.